These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 1889331)

  • 1. [Determination of praziquantel levels in cerebrospinal fluid and plasma in patients with cysticercosis of the central nervous system treated with praziquantel].
    Jia JY
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1991 Jun; 24(3):174-6, 189-90. PubMed ID: 1889331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preliminary report of praziquantel treatment of cysticercosis patients in Vietnam.
    Pham HT; van Knapen F
    Acta Leiden; 1989; 57(2):229-33. PubMed ID: 2489001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma pharmacokinetics and therapeutic efficacy of praziquantel and 4-hydroxypraziquantel in Schistosoma japonicum-infected rabbits after oral, rectal, and intramuscular administration.
    Xiao SH; You JQ; Guo HF
    Am J Trop Med Hyg; 1992 May; 46(5):582-8. PubMed ID: 1599052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma concentrations of praziquantel during the therapy of neurocysticerosis with praziquantel, in the presence of antiepileptics and dexamethasone.
    Na-Bangchang K; Vanijanonta S; Karbwang J
    Southeast Asian J Trop Med Public Health; 1995 Mar; 26(1):120-3. PubMed ID: 8525397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparative analysis of the influence of food and cimetidine in plasma levels of praziquantel].
    Castro N; González-Esquivel DF; López M; Jung H
    Rev Invest Clin; 2003; 55(6):655-61. PubMed ID: 15011735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cerebral cysticercosis treated with praziquantel--a case report].
    Shimamoto Y; Sugiyama E; Inaba M; Shinoda J; Shimazaki K; Yamada F
    No To Shinkei; 1994 Apr; 46(4):381-6. PubMed ID: 8024838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Penetration of praziquantel into cerebrospinal fluid and cysticerci in human cysticercosis.
    Overbosch D; van de Nes JC; Groll E; Diekmann HW; Polderman AM; Mattie H
    Eur J Clin Pharmacol; 1987; 33(3):287-92. PubMed ID: 3691616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic optimisation of the treatment of neurocysticercosis.
    Sotelo J; Jung H
    Clin Pharmacokinet; 1998 Jun; 34(6):503-15. PubMed ID: 9646011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacokinetics of praziquantel.
    Jung H; Vazquez ML; Sanchez M; Penagos P; Sotelo J
    Proc West Pharmacol Soc; 1991; 34():335-40. PubMed ID: 1788307
    [No Abstract]   [Full Text] [Related]  

  • 10. Enhancement the oral bioavailability of praziquantel by incorporation into solid lipid nanoparticles.
    Yang L; Geng Y; Li H; Zhang Y; You J; Chang Y
    Pharmazie; 2009 Feb; 64(2):86-9. PubMed ID: 19320279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The treatment of neurocysticercosis with praziquantel.
    Vanijanonta S; Bunnag D; Riganti M
    Southeast Asian J Trop Med Public Health; 1991 Dec; 22 Suppl():275-8. PubMed ID: 1822905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of therapeutic regimen of anticysticercal drugs for parenchymal brain cysticercosis.
    Sotelo J; del Brutto OH; Penagos P; Escobedo F; Torres B; Rodriguez-Carbajal J; Rubio-Donnadieu F
    J Neurol; 1990 Apr; 237(2):69-72. PubMed ID: 2192018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical evaluation of the therapeutic efficacy of praziquantel against human cysticercosis.
    Rim HJ; Joo KH
    Acta Leiden; 1989; 57(2):235-45. PubMed ID: 2489002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of the efficacy of praziquantel-liposome against alveococcosis].
    Li FR; Jiang CP; Cao HX; Wang Q
    Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 1993; 11(4):251-4. PubMed ID: 8082262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Humoral immune response in patients with cerebral parenchymal cysticercosis treated with praziquantel.
    Estañol B; Juárez H; Irigoyen Mdel C; González-Barranco D; Corona T
    J Neurol Neurosurg Psychiatry; 1989 Feb; 52(2):254-7. PubMed ID: 2703841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Medical treatment of cerebral cysticercosis].
    Robles Castillo C
    Salud Publica Mex; 1981; 23(5):443-50. PubMed ID: 7330723
    [No Abstract]   [Full Text] [Related]  

  • 17. Praziquantel in the cerebrospinal fluid in neurocysticercosis.
    Spina-França A; Machado LR; Nóbrega JP; Livramento JA; Diekmann HW; Groll E; de Rezende GL
    Arq Neuropsiquiatr; 1985 Sep; 43(3):243-59. PubMed ID: 4091736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enantioselective analysis of praziquantel and trans-4-hydroxypraziquantel in human plasma by chiral LC-MS/MS: Application to pharmacokinetics.
    Lima RM; Ferreira MA; Ponte TM; Marques MP; Takayanagui OM; Garcia HH; Coelho EB; Bonato PS; Lanchote VL
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Oct; 877(27):3083-8. PubMed ID: 19665946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A clinical study on the treatment of cerebral cysticercosis with praziquantel].
    Ma YX
    Zhonghua Yi Xue Za Zhi; 1984 Feb; 64(2):79-83. PubMed ID: 6432251
    [No Abstract]   [Full Text] [Related]  

  • 20. Successful treatment of neurocysticercosis with low-dose praziquantel.
    Pun KK; Wong WT
    Trop Geogr Med; 1984 Sep; 36(3):303-4. PubMed ID: 6506211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.